Bleiben Sie auf dem Laufenden

The challenge of inspecting injectable products has grown significantly in recent years. The future of sterile manufacturing will depend on systems capable of combining speed, precision, automation, and data intelligence into a unified quality strategy.

The medac group brings its production sites in Dessau and Brno together under the corporate brand medac. As of 1 April 2026, the former companies Oncotec Pharma Produktion GmbH and oncomed manufacturing a.s. operate under the name medac pharma production.

medac CDMO is partnering with UroGen Pharma to support the development and supply chain of UGN-103 using its licensed mitomycin formulation and manufacturing services.

Within medac CDMO, we have successfully completed the NaDiNa project, whose main objective was to develop a formulation, establish a manufacturing process, and prepare a prototype of a novel anticancer drug up to the stage enabling its clinical evaluation. The project was carried out in close collaboration with the Faculty of Medicine of Palacký University in Olomouc (UPOL) and was financially supported by the Technology Agency of the Czech Republic (TAČR).

The recent completion of patient enrollment in UroGen Pharma’s Phase 3 UTOPIA trial marks a major step forward in the development of UGN-103 (mitomycin) for intravesical solution under investigation for the treatment of recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). medac CDMO is proud to contribute significantly to this achievement as the development and manufacturing partner for UGN-103....